Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer

F. M. Muggia, Fernando J. Camacho, B. H. Kaplan, M. D. Green, E. S. Greenwald, J. C. Wernz, P. F. Engstrom

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU. However, future studies with this combination utilizing the current or other previously published schedules are not warranted in colorectal cancer. Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures.

Original languageEnglish (US)
Pages (from-to)253-256
Number of pages4
JournalCancer Treatment Reports
Volume71
Issue number3
StatePublished - Jun 5 1987
Externally publishedYes

Fingerprint

NSC 224131
Poisons
Therapeutic Uses
Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Conjunctivitis
Exanthema
Vomiting
Diarrhea
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Muggia, F. M., Camacho, F. J., Kaplan, B. H., Green, M. D., Greenwald, E. S., Wernz, J. C., & Engstrom, P. F. (1987). Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer. Cancer Treatment Reports, 71(3), 253-256.

Weekly 5-fluorouracil combined with PALA : Toxic and therapeutic effects in colorectal cancer. / Muggia, F. M.; Camacho, Fernando J.; Kaplan, B. H.; Green, M. D.; Greenwald, E. S.; Wernz, J. C.; Engstrom, P. F.

In: Cancer Treatment Reports, Vol. 71, No. 3, 05.06.1987, p. 253-256.

Research output: Contribution to journalArticle

Muggia, FM, Camacho, FJ, Kaplan, BH, Green, MD, Greenwald, ES, Wernz, JC & Engstrom, PF 1987, 'Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer', Cancer Treatment Reports, vol. 71, no. 3, pp. 253-256.
Muggia FM, Camacho FJ, Kaplan BH, Green MD, Greenwald ES, Wernz JC et al. Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer. Cancer Treatment Reports. 1987 Jun 5;71(3):253-256.
Muggia, F. M. ; Camacho, Fernando J. ; Kaplan, B. H. ; Green, M. D. ; Greenwald, E. S. ; Wernz, J. C. ; Engstrom, P. F. / Weekly 5-fluorouracil combined with PALA : Toxic and therapeutic effects in colorectal cancer. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 3. pp. 253-256.
@article{dd73aa6c4dbc4228b2a6c41d6f28f586,
title = "Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer",
abstract = "A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU. However, future studies with this combination utilizing the current or other previously published schedules are not warranted in colorectal cancer. Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures.",
author = "Muggia, {F. M.} and Camacho, {Fernando J.} and Kaplan, {B. H.} and Green, {M. D.} and Greenwald, {E. S.} and Wernz, {J. C.} and Engstrom, {P. F.}",
year = "1987",
month = "6",
day = "5",
language = "English (US)",
volume = "71",
pages = "253--256",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Weekly 5-fluorouracil combined with PALA

T2 - Toxic and therapeutic effects in colorectal cancer

AU - Muggia, F. M.

AU - Camacho, Fernando J.

AU - Kaplan, B. H.

AU - Green, M. D.

AU - Greenwald, E. S.

AU - Wernz, J. C.

AU - Engstrom, P. F.

PY - 1987/6/5

Y1 - 1987/6/5

N2 - A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU. However, future studies with this combination utilizing the current or other previously published schedules are not warranted in colorectal cancer. Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures.

AB - A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU. However, future studies with this combination utilizing the current or other previously published schedules are not warranted in colorectal cancer. Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures.

UR - http://www.scopus.com/inward/record.url?scp=0023150341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023150341&partnerID=8YFLogxK

M3 - Article

C2 - 3815391

AN - SCOPUS:0023150341

VL - 71

SP - 253

EP - 256

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -